Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAFW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) provide detailed insight into the company’s biotechnology business, capital structure and diagnostic platform for early lung cancer detection. Registration statements on Form S-1 and Form S-3, along with related amendments, describe offerings of common stock, Series B Convertible Preferred Stock and multiple series of warrants to purchase common stock, including their terms, exercise prices, anti-dilution provisions and resale registration arrangements for selling stockholders.
Through periodic reports and current reports on Form 8-K, bioAffinity discloses operating and financial information related to CyPath® Lung and its subsidiary Precision Pathology Laboratory Services (PPLS). These filings discuss revenue from CyPath® Lung testing and pathology services, research and clinical development expenses, and strategic decisions such as discontinuing certain unprofitable pathology services to focus resources on commercialization of the CyPath® Lung test.
Filings also document corporate actions and listing matters, including a one-for-thirty reverse stock split approved and implemented to address Nasdaq minimum bid price requirements, and subsequent confirmation that the company regained compliance with Nasdaq continued listing standards. Investors reviewing BIAFW often use these documents to understand how changes in capital structure, such as new warrant issuances or amendments to floor prices, affect potential dilution and warrant economics.
bioAffinity’s SEC disclosures further outline its intellectual property position, describing patents that protect the AI-built algorithm and flow cytometry platform used in CyPath® Lung and other diagnostics in development. While the full text of annual reports (Form 10-K) and quarterly reports (Form 10-Q) is not reproduced here, those filings typically provide comprehensive risk factor discussions, management’s analysis of operations and liquidity, and additional detail on the company’s biotechnology programs.
On Stock Titan’s filings page, users can access real-time updates from EDGAR, including 8-K current reports on material events, registration statements related to equity financings and warrants, and periodic reports. AI-powered summaries help explain key elements of complex filings, highlight changes in capital structure, and surface information relevant to BIAFW warrant holders and equity investors, such as reverse stock split terms, warrant adjustments and use of proceeds from offerings.
bioAffinity Technologies, Inc. filed a current report to furnish updated presentation materials about the company’s operations and performance. Management intends to use these February 2026 presentation slides in meetings, and the materials were posted to the company’s website on February 10, 2026.
The materials are furnished under Regulation FD as Exhibit 99.1 and are expressly not deemed “filed” for liability purposes under the Securities Exchange Act of 1934 or incorporated by reference into other Securities Act or Exchange Act filings.
bioAffinity Technologies filed an 8-K reporting that it has expanded its Medical and Scientific Advisory Board by appointing three nationally recognized pulmonary and lung cancer specialists: Dr. David Ost of MD Anderson Cancer Center, Dr. Daniel Sterman of NYU Langone Health, and Dr. J. Scott Ferguson of the University of Wisconsin School of Medicine and Public Health.
The company develops CyPath® Lung, a noninvasive diagnostic test for early detection of lung cancer in high-risk patients with small indeterminate pulmonary nodules. In clinical studies, CyPath® Lung showed 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer, supporting its role as an added tool to inform clinicians and potentially improve early-stage diagnosis.
bioAffinity Technologies, Inc. has scheduled its 2026 Annual Meeting of Stockholders for April 30, 2026 at its principal executive offices in San Antonio, Texas. The company plans to include at this meeting the proposals from a prior Special Meeting that was convened on December 19, 2025 but adjourned without business because a quorum of common stockholders was not present.
Stockholders who wish to bring business before the 2026 Annual Meeting or nominate directors must deliver written notice to the company’s principal executive offices by February 14, 2026, in accordance with the detailed requirements of the company’s Amended and Restated Bylaws.
bioAffinity Technologies, Inc. filed a Current Report on Form 8-K disclosing a corporate action: the company announced a Reverse Stock Split and furnished a related press release dated September 17, 2025. The filing also includes a Certificate of Amendment to the Certificate of Incorporation as Exhibit 3.1, and the press release is furnished as Exhibit 99.1. The 8-K indicates these documents are part of the company's report of a material event but does not provide the split ratio or detail any effects on shares outstanding, shareholder approvals, or listing status within the disclosed text.
bioAffinity Technologies, Inc. filed an amended prospectus to register up to 32,495,628 shares of common stock for resale by existing investors and other selling stockholders. These resale shares include stock issuable upon conversion of Series B preferred stock and upon exercise of several sets of warrants, including Private Warrants, Inducement Warrants, May 2025 Warrants and advisor and placement agent warrants.
The company itself is not selling shares in this offering and will not receive proceeds from stockholder resales, but may receive cash if investors convert the preferred stock or exercise the registered warrants. The filing stems from recent financings and warrant inducement transactions completed in August 2025 and related anti-dilution adjustments to May 2025 warrants.
bioAffinity develops noninvasive diagnostics such as its CyPath® Lung test for early-stage lung cancer and continues to advance additional lung disease diagnostics and oncology therapeutic research while operating as an emerging growth and smaller reporting company.
bioAffinity Technologies, Inc. filed a current report to share a corporate update. On September 9, 2025, the company issued a press release announcing the release of a new case study involving its CyPath® Lung test. The case study describes how CyPath® Lung identified cancer in a patient who had an incidental finding of ground glass nodules. The press release is included with the report as an exhibit, making the information part of the company’s official disclosures.
bioAffinity Technologies, Inc. furnished an investor presentation under a Regulation FD disclosure. The company plans to use these presentation materials to discuss its operations and performance, including at the H.C. Wainwright 27th Annual Global Investment Conference held from September 8–10, 2025. The presentation is attached as Exhibit 99.1 to the report and is provided for informational purposes only. It is expressly stated as being "furnished" rather than "filed," which means it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings.
bioAffinity Technologies, Inc. filed an update describing media coverage of its CyPath® Lung diagnostic test. On September 3, 2025, the company issued a press release noting that U.S. Medicine Magazine featured CyPath® Lung in its pulmonary issue. The article highlights the test’s potential to improve lung cancer detection while lowering costs for the U.S. Department of Veterans Affairs.
The press release is included in this report as an exhibit, providing additional detail on how CyPath® Lung is being positioned in the clinical community.
bioAffinity Technologies, Inc. entered into amendments to two series of outstanding warrants. Effective as of August 12, 2025, the Company and the warrant holders agreed to raise the Floor Price in both the May 2025 Warrants and the August 2025 Warrants from $0.10 to $0.15 per share. This change reduced the total number of shares issuable upon exercise of the May 2025 Warrants from 53,377,497 to 35,584,997, meaning fewer shares can be issued if those warrants are fully exercised. The August 2025 Warrants remain subject to shareholder approval, and the detailed amendment terms are provided in the attached warrant amendment exhibits.
bioAffinity Technologies, Inc. is registering up to 12,611,253 shares of common stock for resale by existing investors. These shares consist of stock issuable on conversion of 990 shares of Series B Convertible Preferred Stock and on exercises of multiple series of common stock warrants issued in August 2025 private financing and warrant inducement transactions.
The company will not receive proceeds from any resale of these shares, but will receive cash if the preferred stock is converted and the warrants are exercised, which it plans to use for working capital and general corporate purposes. The registered securities relate to an August 2025 private placement that raised about $1.2 million in gross proceeds and a warrant inducement transaction that raised about $253,000.
bioAffinity develops noninvasive diagnostics, including its CyPath® Lung test for early-stage lung cancer, and is advancing additional lung disease diagnostics and oncology research. The filing highlights significant risks, including a going-concern funding need, heavy reliance on its laboratory subsidiary, and ongoing Nasdaq compliance issues following notices for minimum bid price and stockholders’ equity deficiencies.
FAQ
What is the current stock price of bioAffinity Tech (BIAFW)?
